Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer

Next Previous
Trial Profile

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 08 Oct 2026 According to a Clarity Pharmaceuticals media release, company announced that the recruitment target of the Cohort Expansion (Main Group) of the Phase I/IIa SECuRE trial has been achieved.The enrolled sixteen participants with metastatic castration-resistant prostate cancer (mCRPC) are being evaluated for the efficacy and safety of up to six cycles of 8 GBq of 67Cu-SAR-bisPSMA.
  • 06 Aug 2026 According to a Clarity Pharmaceuticals media release, Nineteen participants from this trial were included in this assessment of the safety and efficacy of the 8 GBq 67Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from the ongoing Cohort Expansion phase (data cut-off: July 20, 2026).
  • 05 Aug 2026 Results presented in the Clarity Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top